# Digital Patient and Drug Response Pipeline - Comprehensive Implementation Plan

## Pipeline Overview
```mermaid
flowchart TB
    subgraph Patient["Patient Profile Generation"]
        A1[1. Medical Records Creation] --> A2[2. Disease-specific Genome]
        A2 --> A3[3. Disease-specific Protein Variants]
        A3 --> A4[4. Disease-specific Transcriptome]
        A4 --> A5[5. Disease-specific Proteome]
        A5 --> A6[6. Disease-specific Metabolome]
        A6 --> A7[7. Disease-specific Immunome]
    end

    subgraph Drug["Drug Analysis & Modeling"]
        B1[8. Drug-Target PK] --> B1a[8a. Binding Site Prediction]
        B1a --> B1b[8b. Drug-Target Docking]
        B1b --> B2[9. Drug-Proteome Screening]
        B2 --> B3[10. Off-target Analysis]
        B3 --> B4[11. Drug-Compound Screening]
        B4 --> B5[12. Drug-Genome Sensitivity]
    end

    subgraph Response["Response Prediction"]
        C1[13. Transcriptomic Changes] --> C2[14. Disease Stage Evaluation]
        C2 --> C3[15-16. Proteomic & Metabolomic Changes]
        C3 --> C4[17-19. Biological & Immune Response]
        C4 --> C5[20-21. ADMET & Toxicity]
    end

    Patient --> Drug
    Drug --> Response
```

## Part 1: Digital Patient Generation

### Implementation Status Overview

| Step | Status | Tool/Method | Input | Output | Location | Validation Data | Dependencies/Notes |
|------|--------|-------------|--------|---------|-----------|-----------------|-------------------|
| 1. Medical Records | ✓ | Synthea | - | Demographics, records | /Workspace/next/registry/tools/synthea | Target: 1000 patients/disease | - |
| 2. Disease Genome | ✓ | Omic-UKBB | Alleles, positions, frequencies | VCF (hg38) | Part of Synthea repo | - | Only storing variants |
| 3. Protein Variants | ✓ | vcf2prot | VCF | Protein fasta | Part of Synthea repo (tbc) | - | Multi-tissue support needed |
| 4. Transcriptome | 🚧 | borzoi | Genomic sequences | RNAseq (TPM) | - | ENCODE, GTEx (E-MTAB-6814) | NIH ENCODE standards |
| 5. Proteome | 🚧 | clei2block | RNAseq (log2-FC) | Fold-change | github.com/stasaki/clei2block | CellModelPassport, TCGA | Requires GTEx training |
| 6. Metabolome | ⏳ | corto | RNAseq (TPM) | Metabolite profiles | github.com/federicogiorgi/corto | CCLE, NCI-60 | - |
| 7. Immunome | ⏳ | Ecotyper | RNAseq | Cell type profiles | - | SPICA30, SPICA17 | - |

### Active Implementation Tasks

#### Transcriptome Generation
Current goal: Establish accurate transcriptome prediction pipeline
- [x] Implement and evaluate primary models:
  * ~~enformer~~
  * ~~basenji~~
  * borzoi ~~for RNAseq profiles~~, built on basenji and enformer
- [x] Add SequenceModelBenchmark ridge regression - built into borzoi (tbc) 
- [ ] Validate against ENCODE standards
- [ ] Implement GTEx validation pipeline

#### Multi-omic Integration
Current goal: Create robust data transformation pipeline
- [ ] Proteome prediction (clei2block):
  * Implement GTEx training pipeline
  * Add multi-tissue support
  * Create validation framework against CellModelPassport
- [ ] Metabolome generation (corto):
  * Setup CCLE data integration
  * Implement NCI-60 validation
- [ ] Immunome profiling:
  * ~~Evaluate Ecotyper vs CIBERTSORTx~~ CIBERTSORTx incorporated within Ecotyper
  * Integrate SPICA datasets
  * Setup immune cell validation pipeline

## Part 2: Drug Discovery and Response

### Drug Development Tools
Current goal: Establish comprehensive drug analysis pipeline
- [ ] Molecule Processing:
  * SELFIES library for biologics/peptides conversion
  * Implement molecule validation checks
  * Setup standardization pipeline
- [ ] Structure Analysis:
  * DreamDock + ConPlex score pipeline
  * LightDock for membrane binding
  * Validation framework with crystal structures

### Binding Site Prediction
Current goal: Create consensus model for binding site prediction
- [ ] Benchmark tools:
  * DiffDock implementation and testing
  * Qvina2 evaluation
  * P2Rank integration
  * FPocket analysis
- [ ] Specific considerations:
  * Allosteric site detection
  * Multiple binding site handling
  * Protein flexibility modeling
- [ ] Validation:
  * BindingDB integration
  * Crystal structure comparison pipeline
  * Edge case testing suite

### Drug-Target Analysis
Current goal: Robust docking and interaction prediction
- [ ] Primary docking pipeline:
  * Uni-mol integration
  * DreamDock implementation
  * Path4Drug integration for pathways
- [ ] Molecule type-specific handling:
  * Small molecule pipeline
  * Biologics pathway
  * PROTACs specific analysis
  * Prodrug processing
- [ ] Interaction analysis:
  * Agonist vs antagonist classification
  * Protein-protein interaction integration
  * Chemical_checker for bioactivity signatures

### Chemical Property Prediction
Current goal: Comprehensive property prediction system
- [ ] Model implementation:
  * Chemprop evaluation
  * Soltrannet integration
  * Custom ADMET model development
- [ ] Property coverage:
  * Solubility prediction
  * BBB penetration
  * Chemical stability
  * Metabolic processing

### Toxicity Prediction Pipeline
Current goal: Multi-faceted toxicity assessment system
- [ ] Core modules:
  * Cardiotoxicity (ion channel) prediction
  * Hepatotoxicity (Phase 1/2 proteins)
  * Nephrotoxicity assessment
  * Lung toxicity prediction
  * Neurotoxicity (BBB criteria)
  * Inflammatory response modeling
  * Bleeding/clotting risk analysis
- [ ] Integration components:
  * Human Protein Atlas tissue proportion estimation
  * Reactome pathway analysis
  * Industry model benchmarking

### Drug Response Analysis
Current goal: Integrated response prediction system
- [ ] Transcriptomic response:
  * LINCS data integration
  * Expression change prediction
  * Tissue-specific effects
- [ ] Multi-omic response:
  * Proteomic change modeling
  * Metabolomic adjustment prediction
  * Immune response profiling
- [ ] Special cases:
  * Multi-drug combinations
  * Time-dependent effects
  * Population-specific responses

## Critical Dependencies & Requirements

| Category | Component | Status | Notes |
|----------|-----------|---------|--------|
| **External Data** | BindingDB | ✓ Available | Binding affinities |
| | LINCS | ✓ Available | Compound effects |
| | PharmGKB | ⏳ Pending | Variant annotations |
| | Human Cell Atlas | ⏳ Pending | Tissue-specific data |
| **Compute** | GPU Cluster | 🚧 Scaling | For enformer/basenji |
| | Storage | ✓ Configured | For variant data |
| | Distribution | ⏳ Planned | For processing |

## Validation Framework

| Dataset | Usage | Status | Notes |
|---------|--------|---------|--------|
| ENCODE | Transcriptomics | ✓ Ready | Primary validation |
| GTEx | Tissue-specific | ✓ Ready | E-MTAB-6814 |
| CCLE/GDSC2 | Cell lines | 🚧 In Progress | Cancer validation |
| TDC | ADMET | ⏳ Planned | Benchmark data |
| Cross-species | Conservation | ⏳ Planned | Evolutionary validation |
| Time-series | Metabolics | ⏳ Planned | Kinetic validation |

## Edge Cases & Special Considerations

### Complex Scenarios
| Scenario | Implementation Status | Handling Strategy |
|----------|---------------------|-------------------|
| Rare variants | 🚧 In Progress | Population frequency weighting |
| Multi-drug combinations | ⏳ Planned | Interaction matrix modeling |
| Time-dependent effects | ⏳ Planned | PK/PD time series modeling |
| Population specificity | 🚧 In Progress | Demographic stratification |

### Special Drug Classes
| Class | Special Requirements | Status |
|-------|---------------------|---------|
| Biologics | Membrane modeling, immunogenicity | ⏳ Planned |
| Prodrugs | Metabolite prediction, activation | 🚧 In Progress |
| Combination therapy | Interaction prediction, timing | ⏳ Planned |
| PROTACs | Protein degradation modeling | ⏳ Planned |

## Case Studies & Validation Examples

| Drug | Outcome | Learning Points | Implementation Status |
|------|---------|----------------|----------------------|
| Amcenestrant | Efficacy failure | Target validation importance | ✓ Integrated |
| Flupirtine | Liver toxicity | Metabolite prediction crucial | 🚧 In Progress |
| Ranitidine | NDMA formation | Chemical stability prediction | ⏳ Planned |
| Multi-drug Examples | Variable | Interaction modeling needed | ⏳ Planned |